{"pmid":32274342,"pmcid":"PMC7132016","title":"COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies.","text":["COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies.","The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19.","J Clin Transl Hepatol","Feng, Gong","Zheng, Kenneth I","Yan, Qin-Qin","Rios, Rafael S","Targher, Giovanni","Byrne, Christopher D","Poucke, Sven Van","Liu, Wen-Yue","Zheng, Ming-Hua","32274342"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19."],"journal":"J Clin Transl Hepatol","authors":["Feng, Gong","Zheng, Kenneth I","Yan, Qin-Qin","Rios, Rafael S","Targher, Giovanni","Byrne, Christopher D","Poucke, Sven Van","Liu, Wen-Yue","Zheng, Ming-Hua"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274342","week":"202015|Apr 06 - Apr 12","doi":"10.14218/JCTH.2020.00018","keywords":["COVID-19","Liver dysfunction","SARS-CoV-2"],"source":"PubMed","topics":["Treatment","Prevention","Diagnosis"],"weight":1,"e_drugs":["Aspartic Acid"],"_version_":1663712077857947648,"score":7.9164424,"similar":[{"pmid":32274341,"pmcid":"PMC7132021","title":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","text":["Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19.","J Clin Transl Hepatol","Li, Jie","Fan, Jian-Gao","32274341"],"abstract":["An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19."],"journal":"J Clin Transl Hepatol","authors":["Li, Jie","Fan, Jian-Gao"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274341","week":"202015|Apr 06 - Apr 12","doi":"10.14218/JCTH.2020.00019","keywords":["COVID-19","Clinical characteristics","Liver injury","Mechanism","SARS-CoV-2"],"source":"PubMed","locations":["Wuhan","China","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1663712077831733248,"score":377.8515},{"pmid":32220017,"title":"Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient.","text":["Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient.","Coronavirus disease 2019 (COVID-19) is highly contagious. It may rapidly progress to acute respiratory distress syndrome (ARDS) and result in multiorgan dysfunction or death in some cases.((1,2)) Here, we report the case of a patient with hepatocellular carcinoma (HCC) who underwent liver transplantation and experienced COVID-19 infection during the perioperative period. This case may help clinicians by alerting them to potential COVID-19 infection in transplant recipients during the outbreak.","Hepatology","Qin, Juanjuan","Wang, Haitao","Qin, Xuan","Zhang, Peng","Zhu, Lihua","Cai, Jingjing","Yuan, Yufeng","Li, Hongliang","32220017"],"abstract":["Coronavirus disease 2019 (COVID-19) is highly contagious. It may rapidly progress to acute respiratory distress syndrome (ARDS) and result in multiorgan dysfunction or death in some cases.((1,2)) Here, we report the case of a patient with hepatocellular carcinoma (HCC) who underwent liver transplantation and experienced COVID-19 infection during the perioperative period. This case may help clinicians by alerting them to potential COVID-19 infection in transplant recipients during the outbreak."],"journal":"Hepatology","authors":["Qin, Juanjuan","Wang, Haitao","Qin, Xuan","Zhang, Peng","Zhu, Lihua","Cai, Jingjing","Yuan, Yufeng","Li, Hongliang"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220017","week":"202013|Mar 23 - Mar 29","doi":"10.1002/hep.31257","source":"PubMed","locations":["multiorgan"],"topics":["Case Report"],"weight":1,"_version_":1663352135042990081,"score":327.31906},{"pmid":32277387,"title":"Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","text":["Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.","Hepatol Int","Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George","32277387"],"abstract":["Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic."],"journal":"Hepatol Int","authors":["Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277387","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10043-z","keywords":["2019-nCoV","COVID-19","Liver transplantation","Management"],"source":"PubMed","locations":["Beijing","China","Beijing"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Diagnosis","Treatment"],"weight":1,"_version_":1663798882904047616,"score":312.01343},{"pmid":32170806,"title":"Liver injury during highly pathogenic human coronavirus infections.","text":["Liver injury during highly pathogenic human coronavirus infections.","The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), the pathogen of 2019 novel coronavirus disease (COVID-19), has posed a serious threat to global public health. The WHO has declared the outbreak of SARS-CoV-2 infection an international public health emergency. Lung lesions have been considered as the major damage caused by SARS-CoV-2 infection. However, liver injury has also been reported to occur during the course of the disease in severe cases. Similarly, previous studies have shown that liver damage was common in the patients infected by the other two highly pathogenic coronavirus - severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), and associated with the severity of diseases. In this review, the characteristics and mechanism of liver injury caused by SARS-CoV, MERS-CoV as well as SARS-CoV-2 infection were summarized, which may provide help for further studies on the liver injury of COVID-19.","Liver Int","Xu, Ling","Liu, Jia","Lu, Mengji","Yang, Dongliang","Zheng, Xin","32170806"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), the pathogen of 2019 novel coronavirus disease (COVID-19), has posed a serious threat to global public health. The WHO has declared the outbreak of SARS-CoV-2 infection an international public health emergency. Lung lesions have been considered as the major damage caused by SARS-CoV-2 infection. However, liver injury has also been reported to occur during the course of the disease in severe cases. Similarly, previous studies have shown that liver damage was common in the patients infected by the other two highly pathogenic coronavirus - severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), and associated with the severity of diseases. In this review, the characteristics and mechanism of liver injury caused by SARS-CoV, MERS-CoV as well as SARS-CoV-2 infection were summarized, which may provide help for further studies on the liver injury of COVID-19."],"journal":"Liver Int","authors":["Xu, Ling","Liu, Jia","Lu, Mengji","Yang, Dongliang","Zheng, Xin"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32170806","week":"202011|Mar 09 - Mar 15","doi":"10.1111/liv.14435","keywords":["COVID-19","MERS","SARS","SARS-CoV-2","liver injury"],"source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663352133968199680,"score":311.29922},{"pmid":32219882,"title":"Controversial treatments: an updated understanding of the Coronavirus Disease 2019.","text":["Controversial treatments: an updated understanding of the Coronavirus Disease 2019.","An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system (ALS) and extracorporeal membrane oxygenation (ECMO), based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively. This article is protected by copyright. All rights reserved.","J Med Virol","Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong","32219882"],"abstract":["An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system (ALS) and extracorporeal membrane oxygenation (ECMO), based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219882","week":"202013|Mar 23 - Mar 29","doi":"10.1002/jmv.25788","keywords":["COVID-19","SARS-CoV-2","coronavirus","literature review","pneumonia","treatment"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"e_drugs":["Ribavirin","Chloroquine"],"_version_":1663352135074447360,"score":310.9427}]}